Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.

Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.

Increasingly, pharmacists are leading the obesity management team.

A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.

Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.

The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.

Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.